23andMe
Tracked across 5 events · 47 articles · First seen Mar 24, 2025 · Last active Jul 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: 23andMe Research Institute, a subsidiary of 23andMe, published a study identifying genetic predictors for GLP-1 weight loss efficacy and side effects, leading to the release of a new report for its Total Health service. This enhances 23andMe's position in personalized medicine.
Apr 08, 2026 · 7 articles
Regulatory
Impact: 23andMe>>> is the genetic testing company at the center of the data breach and subsequent lawsuits. Its reputation and financial standing have been severely impacted, leading to bankruptcy and asset sale.
May 28, 2026 · 21 articles
Business
Impact: 23andMe is the defendant in the data breach class action and the subject of the approved settlement. The company filed for bankruptcy and was sold, with its legal name now Chrome Holding Co. The settlement and ongoing United States — California lawsuit represent significant liabilities.
Jul 07, 2026 · 6 articles
Regulatory
Impact: Central entity; suffered a major data breach, bankruptcy, and now an $18M settlement; its assets were sold to a nonprofit.
Jul 14, 2026 · 6 articles
Regulatory
Impact: 23andMe's co-founder Anne Wojcicki provided input as an unpaid consultant for Kalshi's initiative.
Jul 16, 2026 · 7 articles
Anne Wojcicki
board member
↔
23andMe
Anne Wojcicki, co-founder of 23andMe, remains on its board of directors followin
ERGEN INTELLIGENCE
Track 23andMe live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard